DDX3Y and B-cell non-Hodgkin lymphoma: In this case, specific DDX3Y inhibitors blocking its enzymatic activity or any other strategy abolishing DDX3Y protein would eliminate the B-cell lymphoma, but not other cells, since DDX3Y is not expressed in most normal cells.